Capina, Essentialis Merger To Create Rare Disease Firm
Executive Summary
The combined company would advance a diazoxide choline controlled-release daily pill for treating patients with Prader-Willi syndrome through pivotal Phase II/III clinical trialing.
You may also be interested in...
Deal Watch: Sanofi Begins 2017 By Ending Vaccine JV, Completing Swap With Boehringer
At year's end the French pharma also announced a restructuring of its broad diabetes collaboration with South Korea’s Hanmi. In a deal involving two other French companies, OSE out-licensed global development and commercial rights to an IL-7 antagonist to Servier.
Strong PhII data in triglyceride reduction attracts partners to Essentialis
Essentialis Inc. is in discussions with partners and potential acquirers as its moves into Phase III clinical trials for diazoxide choline controlled-release tablets, or DCCR, a drug that may cause dramatic reductions in triglyceride levels for high-risk patients who already are taking cholesterol-lowering medications.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.